Mission, EffRx sign agreement for osteoporosis drug

Binosto scheduled for launch in late 2012

SAN ANTONIO — A U.S. drug maker has made a deal with a Swiss company to manufacture and sell a new osteoporosis treatment in North America.

Mission Pharmacal announced Tuesday a patent and technology licensing agreement with Freienbach, Switzerland-based EffRx Pharmaceuticals for Binosto (alendronate sodium) effervescent tablets in the United States and Canada. Financial terms were not disclosed.

The Food and Drug Administration approved the drug last month for osteoporosis in men and postmenopausal women. The companies plan to make the drug available later this year. The drug is a strawberry-flavored effervescent tablet designed to rapidly dissolve in water.

"Binosto provides an important new innovation for patients with osteoporosis," National Osteoporosis Foundation president Robert Recker said. "Binosto offers those patients that struggle with taking tablets the opportunity to obtain the proven fracture prevention of alendronate in an easy-to-take, buffered solution."

Poll

Poll

SPECIAL REPORTS

Are we in the midst of a beauty revolution? Perhaps. It is no secret that the ever-changing beauty category is all about trends, but one could argue that we are embarking on an especially interesting time in beauty as technology is changing the way consumers shop and new innovations strive to break through the noise.

In this beauty report, Drug Store News takes a deeper dive into some of the leading trends that are reshaping beauty.more ...

IN THIS ISSUE

In this issue, DSN examines PricewaterhouseCoopers' "Top Health Industry Issues for 2015;" takes you on a tour of Murad, shares beauty trends and insights and delves into location-based technology and how it is revolutionizing health, retail.Click here to view the issue.